Anti-Telomerase reverse transcriptase (phospho S824) antibody (ab63558)

Overview

  • Product nameAnti-Telomerase reverse transcriptase (phospho S824) antibodySee all Telomerase reverse transcriptase primary antibodies ...
  • Description
    Rabbit polyclonal to Telomerase reverse transcriptase (phospho S824)
  • Specificityab63558 detects endogenous levels of TERT only when phosphorylated at serine 824.
  • Tested applicationsELISA, WB more details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    synthesized phosphopeptide derived from human Telomerase around the phosphorylation site of serine 824 (G-K-SP-Y-V).

  • Positive control
    • extracts from COLO205 cells

Properties

Applications

Our Abpromise guarantee covers the use of ab63558 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
ELISA 1/10000.
WB 1/500 - 1/1000. Predicted molecular weight: 127 kDa.

Target

  • FunctionTelomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The catalytic cycle involves primer binding, primer extension and release of product once the template boundary has been reached or nascent product translocation followed by further extension. More active on substrates containing 2 or 3 telomeric repeats. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. Modulates Wnt signaling. Plays important roles in aging and antiapoptosis.
  • Tissue specificityExpressed at a high level in thymocyte subpopulations, at an intermediate level in tonsil T lymphocytes, and at a low to undetectable level in peripheral blood T lymphocytes.
  • Involvement in diseaseNote=Activation of telomerase has been implicated in cell immortalization and cancer cell pathogenesis.
    Defects in TERT are associated with susceptibilty to aplastic anemia (AA) [MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis.
    Note=Genetic variations in TERT are associated with coronary artery disease (CAD).
    Defects in TERT are a cause of dyskeratosis congenita autosomal dominant (ADDKC) [MIM:127550]; also known as dyskeratosis congenita Scoggins type. ADDKC is a rare, progressive bone marrow failure syndrome characterized by the triad of reticulated skin hyperpigmentation, nail dystrophy, and mucosal leukoplakia. Early mortality is often associated with bone marrow failure, infections, fatal pulmonary complications, or malignancy.
    Defects in TERT are a cause of susceptibility to pulmonary fibrosis idiopathic (IPF) [MIM:178500]. Pulmonary fibrosis is a lung disease characterized by shortness of breath, radiographically evident diffuse pulmonary infiltrates, and varying degrees of inflammation and fibrosis on biopsy. It results in acute lung injury with subsequent scarring and endstage lung disease.
  • Sequence similaritiesBelongs to the reverse transcriptase family. Telomerase subfamily.
    Contains 1 reverse transcriptase domain.
  • DomainThe primer grip sequence in the RT domain is required for telomerase activity and for stable association with short telomeric primers.
    The RNA-interacting domain 1 (RD1)/N-terminal extension (NTE) is required for interaction with the pseudoknot-template domain of each of TERC dimers. It contains anchor sites that bind primer nucleotides upstream of the RNA-DNA hybrid and is thus an essential determinant of repeat addition processivity.
    The RNA-interacting domain 2 (RD2) is essential for both interaction with the CR4-CR5 domain of TERC and for DNA sythesis.
  • Post-translational
    modifications
    Ubiquitinated, leading to proteasomal degradation.
    Phosphorylation at Tyr-707 under oxidative stress leads to translocation of TERT to the cytoplasm and reduces its antiapoptotic activity. Dephosphorylated by SHP2/PTPN11 leading to nuclear retention. Phosphorylation by the AKT pathway promotes nuclear location.
  • Cellular localizationNucleus > nucleolus. Nucleus > nucleoplasm. Nucleus. Chromosome > telomere. Cytoplasm. Nucleus > PML body. Shuttling between nuclear and cytoplasm depends on cell cycle, phosphorylation states, transformation and DNA damage. Diffuse localization in the nucleoplasm. Enriched in nucleoli of certain cell types. Translocated to the cytoplasm via nuclear pores in a CRM1/RAN-dependent manner involving oxidative stress-mediated phosphorylation at Tyr-707. Dephosphorylation at this site by SHP2 retains TERT in the nucleus. Translocated to the nucleus by phosphorylation by AKT.
  • Target information above from: UniProt accession O14746 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
    • EST2 antibody
    • hEST2 antibody
    • htert antibody
    • TCS1 antibody
    • Telomerase associated protein 2 antibody
    • Telomerase Catalytic Subunit antibody
    • Telomerase reverse transcriptase antibody
    • Telomerase-associated protein 2 antibody
    • Telomere Reverse Transcriptase antibody
    • TERT antibody
    • TERT_HUMAN antibody
    • TP2 antibody
    • TRT antibody
    see all

Anti-Telomerase reverse transcriptase (phospho S824) antibody images

  • All lanes : Anti-Telomerase reverse transcriptase (phospho S824) antibody (ab63558) at 1/500 dilution

    Lane 1 : extracts from COLO205 cells
    Lane 2 : extracts from COLO205 cells plus immunising peptide at 10ug

    Lysates/proteins at 30 µg per lane.


    Predicted band size : 127 kDa
    Observed band size : 130 kDa (why is the actual band size different from the predicted?)

References for Anti-Telomerase reverse transcriptase (phospho S824) antibody (ab63558)

This product has been referenced in:
  • Akiyama M  et al. Telomerase activation as a repair response to radiation-induced DNA damage in Y79 retinoblastoma cells. Cancer Lett 340:82-7 (2013). WB ; Human . Read more (PubMed: 23850566) »
  • Deeb D  et al. Inhibition of cell proliferation and induction of apoptosis by oleanane triterpenoid (CDDO-Me) in pancreatic cancer cells is associated with the suppression of hTERT gene expression and its telomerase activity. Biochem Biophys Res Commun 422:561-7 (2012). WB ; Human . Read more (PubMed: 22609405) »

See all 2 Publications for this product

Product Wall

Application Western blot
Sample Human Cell lysate - whole cell (DU145 Prostate Cancer Cells)
Loading amount 50 µg
Specification DU145 Prostate Cancer Cells
Treatment Control, POH or
Gel Running Conditions Reduced Denaturing (4-15% polyacrylamide TGX mini-gel (Bio-Rad))
Blocking step protein-free bløk-CH™ buffer (Millipore) as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 100% · Temperature: 21°C
Username

Dr. Tabetha Sundin

Verified customer

Submitted Aug 24 2012

Thank you for your call today and for letting us know about the problem with ab63558 in Western blot. As we discussed, I am sending a fresh vial free of charge on the order ***. Since this vial is being transferred from our UK stock, it will ta...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"